GLP-1 Drugs Show Protective Effects Against Addictions, Parkinson's, and Endometrial Cancer
Mar 05, 2026
New research reveals GLP-1 receptor agonists reduce substance use disorders by 14%, lower Parkinson's disease risk after 5-10 years of use, and cut endometrial cancer risk by 66% when combined with progestin therapy.